In a follow up study presenting 96 week results, cabotegravir and rilpivirine long-acting therapy is still non-inferior to oral therapy for HIV, had acceptable safety profiles and resulted in durable virologic suppression. https://www.nature.com/articles/s41591-025-04041-7
Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial - Nature Medicine
In this follow-up study presenting results at 96 weeks, cabotegravir and rilpivirine long-acting therapy remained noninferior to oral therapy, had acceptable safety and tolerability profiles, and resulted in durable virologic suppression, further supporting its consideration for African treatment programs.
www.nature.com
November 6, 2025 at 4:48 PM